
usd feb pm et
summari compani design manufactur market invisalign proprietari system
treat malocclus misalign teeth
price-to-earnings oper ep
risk assess reflect histor volatil
natur demand elect medic procedur
 oversea compani rel narrow
product focu increas risk revenu
shortfal rel compani guidanc
forecast threat legal battl
protect compani intellectu properti
apr ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb stock trade
expect revenu grow
follow growth
expect continu strong growth
intern region increas
penetr teen market key
driver volum growth averag sell
price asp remain flat
expect oper margin fall
primarili intend reorgan
corpor structur continu
invest market expans
intern oper expect
margin much stronger
invest earli
sell product razorblad model
proprietari scanner use
gener invisalign treatment thu
increas sale scanner like lead
increas sale align despit
market concern competit pressur
scanner sale
suggest continu drive high
sale growth next year
posit domin scanner market
competitor su
think strong buy
unwarr sell-off left
trade less peak share
price sequenti declin
world-wide investor concern
lower spur competit
pressur manag attribut declin
short-term promot activ
reason disbeliev see long-term
strength busi driven
increas scanner sale increas
penetr teen foreign market
sum think competit threat
overst compani
pois sustain strong invisalign sale
growth come quarter
risk recommend price includ
intensifi competit sharp declin
customer/competitor pushback
practic weaker-than-expect growth
key end market
target base
ep estim
premium warrant given top-lin
growth expect compar algn
three-year forward pe rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice-president corpor
legal affair chief
cfo senior vice-president global
senior vice presid
senior vice-president
inc oper two segment clear align scanner servic clear
align segment consist invisalign system includ invisalign full express/lit teen assist
vivera retain along train ancillari product treat malocclus scanner
servic segment consist intra-or scan system addit servic avail
intra-or scanner provid digit altern tradit cast model segment includ
itero scanner ioc scanner orthocad servic
compani goal establish invisalign clear align standard method treat
malocclus establish itero intra-or scanner prefer scan protocol digit
scan drive increas product adopt dental profession
clear align segment gener total compani revenu align design manufactur
market invisalign system treat malocclus misalign teeth invisalign
correct malocclus use seri clear remov applianc move teeth desir final
posit distribut major product directli custom includ orthodontist
gener practition dentist compani think malocclus affect billion peopl
popul develop countri accord ten million peopl major
develop countri annual elect treatment orthodontist six million mild
moder malocclus applic invisalign treatment
invisalign system sold north america europ asia pacif latin america japan product
includ invisalign full invisalign express invisalign teen invisalign assist vivera retain ancillari
product malocclus primarili treat metal arch wire bracker refer
brace augment brace elast metal band headgear ancillari devic need
addit juli compani enter suppli agreement smiledirectclub sdc
manufactur non-invisalgn clear align sdc doctor-l at-hom program simpl teeth
align invisalign full use treatment rang malocclus invisalign express solut
less complex orthodont case invisalign teen includ featur complianc indic
help gaug patient wear complianc specialti engin align featur address natur
erupt key teeth common teen patient invisalign assist design specif gener
practition want integr approach select monitor finish invisalign case
ancillari product includ clean materi adjust tool use dental profession
cours treatment
invisalign system offer rang treatment option special servic proprietari softwar
treatment visual compris sever phase princip step invisalign system
creation custom digit treatment plan use proprietari softwar known clincheck
softwar manufactur custom invisalign align dental profession final approv
propos clincheck treatment plan engag align manufactur correspond mold
align mold align fabric align thin clear plastic remov dental
applianc custom manufactur seri correspond two-week stage
scanner servic segment gener total revenu itero intraor scanner
use gener practition prosthodontist periodontist oral surgeon includ
featur restor procedur commonli perform practic veneer inlay onlay
crown bridg implant ioc intra-or scanner use orthodontist digit record
storag orthodont diagnosi comput aid placement tradit brace invisalign digit
impress submiss fabric print model retain orthodont applianc
itero dual scanner includ itero restor softwar ioc orthodont
softwar allow multiple-specialti practic util one intra-or scanner servic scan
need includ crown bridg implant orthodont treatment
domin orthodont scanner market accord primari competitor
scanner market share us orthodont treatment scanner market fallen
precipit stop accept scan anti-trust complaint file
august estim manufactur sell least clear
align us complaint also highlight itero scanner close system design
specif send digit scan order invisalign clear align dental profession
send digit scan rival clear align incur addit fee cost henc dental
profession effect lock exclus order invisalign purchas itero
scanner may point competitor scanner market howev
sirona cerec omnicam definit scanner primarili design orthodont
treatment result take much longer scan patient entir mouth itero trio
decemb estim would take least two year anti-trust case
make trial assum claim surviv align pend motion dimiss
eventu pre-trial motion word see complaint signific risk
near futur
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
technolog export howev
chines govern seek lower
health care cost provid better health
care henc think medic suppli
manufactur particularli
advanc product better insul
industri
 health suppli index
declin vs decreas
neutral fundament outlook
health care suppli sub-industri next
month near-term see price
pressur decreas insur individu
long run demand health care
suppli like continu driven
replac cycl grow same-facil
patient admiss increasingli
fuel age longer-liv popul
basic hospit suppli steril
equip bed stretcher
histor recession-resist
sub-industri robust sale growth
emerg market recent year
expect continu drive growth
sub-industri slowdown emerg market
could significantli dampen growth health
view health care reform law enact
afford act
neutral effect health care suppli
sub-industri benefit greater
number insur patient off-set
price pressur fee possibl threat
state health care system
lawsuit texa rule
unconstitut current
appeal expect upheld upon
appeal although think decis
could take coupl year reach
democrat take control hous
repres expect lower level
effort republican trump
administr tri repeal
democrat unlik support
repeal form
impact trade war appear mild
far medic suppli compani accord
medic devic trade associ advam
china impos septemb retaliatori
tariff billion medic
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
hold buy rais target
above-p ep estim
downgrad hold primarili valuat call forward price-to-earnings ratio current
high-end rang still think
algn growth opportun tremend recent month- long ralli
algn stock price substanti surpass target price rais fy
dec ep estim fy ep estim
inc keep target price
ep estim premium peer compani three-year forward
averag price-to-earnings sale growth continu acceler rais
ep estim
report oper ep vs consensu
sale increas growth total case shipment driven
growth case teenag patient expect sale growth
driven acceler growth emea region well recent
upcom product launch plan launch invisalign first juli
new treatment design specif younger patient addit
compani expect invisalign teen mandibular advanc product
receiv fda approv second half product
expand algn potenti custom base support strong top-lin
inc rais target
ep estim compar five-year histor averag price-to-earnings
balanc strong sale growth outlook expect modest
margin compress higher manufactur spend rais ep
estim set ep
vs consensu sale increas driven
higher-than-expect volum see sale growth aid
intern expans stabl increas invest custom
analyst research note compani news
pm et cfra maintain strong buy opinion share
maintain target above-p
multipl ep estim compar
forward pe rang ep vs
higher estim lower ep
initi ep sale increas million
total invisalign case shipment thousand itero
scanner servic revenu teenag case
intern case world-wide averag
sell price asp increas sequenti intern asp
declin declin promot discount higher
growth non-comprehens case unfavor foreign exchang think
concern competit pressur relat recent lower
overblown compani still well-posit phenomen long-term
pm et cfra upgrad opinion share strong
buy hold upgrad opinion share
think magnitud sell-off past month
unwarr current trade less peak share price
investor concern sequenti declin
world-wide averag sell price asp suggest increas
competit pressur believ asp declin short term
see long-term strength busi driven increas scanner sale
itero scanner servic revenu sinc sell
product razorblad model increas sale scanner like lead
increas sale align accord primari competitor
scanner market share us orthodont treatment scanner market
fallen precipit sum think competit
threat overst pois sustain strong
invisalign sale come quarter /kevin huang cfa
et cfra maintain hold opinion share align
technolog inc lower target
above-p ep estim
stock price still warrant premium sustain high
growth rate comfort margin lower multipl substanti
world-wide averag sell price asp fell sequenti
foreign exchang movement promot program mix shift ep
vs higher estim lower ep
ep sale increas
million total invisalign case shipment
thousand itero scanner servic revenu global
strength drove itero revenu growth set futur case growth
continu market teenag demograph shown
year-over-year increas teenag invisalign case perform
remain robust case ship increas /kevin huang cfa
et cfra maintain hold opinion share align
technolog inc rais target
above-p ep estim stock
price warrant premium sustain high growth rate
comfort margin ep vs higher
estim rais ep ep
sale increas million total invisalign case
shipment thousand itero scanner servic
revenu continu success market teenag
demograph evidenc year-over-year increas teenag
invisalign case growth remark averag sell
price year-over-year number case ship increas
expect food drug administr fda approv
mandibular advanc product /kevin huang cfa
et cfra lower opinion share align technolog inc
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
